TrialESMO open2026

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials.

K Jhaveri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.